Insider Selling: Glaukos Co. (NYSE:GKOS) COO Sells 2,275 Shares of Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Glaukos Price Performance

GKOS stock traded down $0.56 during midday trading on Friday, reaching $131.70. The stock had a trading volume of 646,196 shares, compared to its average volume of 569,709. The company has a market cap of $7.24 billion, a price-to-earnings ratio of -40.89 and a beta of 1.02. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $139.51. The company’s fifty day simple moving average is $129.70 and its 200 day simple moving average is $119.17. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The business had revenue of $95.70 million for the quarter, compared to analysts’ expectations of $88.86 million. During the same period in the previous year, the firm posted ($0.55) EPS. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, sell-side analysts predict that Glaukos Co. will post -2.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

GKOS has been the subject of a number of analyst reports. Citigroup downgraded shares of Glaukos from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $130.00 to $132.00 in a research report on Wednesday, July 10th. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Truist Financial raised their price objective on Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a report on Monday, October 14th. Needham & Company LLC upped their target price on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley increased their target price on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $130.45.

Institutional Trading of Glaukos

Hedge funds and other institutional investors have recently modified their holdings of the business. Values First Advisors Inc. acquired a new position in Glaukos during the 3rd quarter worth approximately $25,000. GAMMA Investing LLC grew its position in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 486 shares during the last quarter. Fifth Third Wealth Advisors LLC purchased a new stake in Glaukos in the 2nd quarter valued at approximately $187,000. Procyon Advisors LLC acquired a new stake in Glaukos in the third quarter valued at $210,000. Finally, Brighton Jones LLC acquired a new stake in shares of Glaukos in the second quarter valued at about $208,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.